p53, a nuclear protein, is believed to play an important role, through mutation and overexpression, in the progression of human malignant tumors. mouse monoclonal antibody NCL-p53-DO7(Novocastra Laboratories Ltd., Newcastle.
England)
which specifically immunoprecipitates mutan-form p53 protein, was used to examine 38 parafifin-embedded ovarian tumor (five mucinous cystadenoma, cne borderline serous cystadenoma, and seven serous cystadenocaricinoma) to find
intranuclear
expression of mutant-form p53 protein.
@ES The results obtained are as follows:
1. In mucinous, and serous cystadenoma, expression of mutant-form p53 protein were negative.
2. In borderline mucinous cystadenoma, two cut of eight of tumors(25%) showed expression of mutant-form p53 protein. However, borderline serous cystadenoma showed negative result.
3. In mucinous cystadenocarcinoma, three out of 11 tumors(27.3%) showed expression of mutant-form p53 protein, and three out of serous cystadenocarcinomas(42.9%) showed
expression of p53 protein. And so, overexpression of p53 protein in serous cystadenocarcionma was more frequent than mucinous cystadenocarcinoma.
4. In comparison between borderline and malignant tumors, approximately same percent of mucinous tumor showed overexpression of p53 protein. However, in serous tumors, borderline tumor that was studied was only one case, same comparison
between
tumors was impossible.
In this study, overexpression of the p53 protein was observed in malignat epithelial tumors of ovary. And this observation suggests that the p53 tumor suppressor gene is involved in the tumorigenessis of malignat ovarian epithelial tumors.
|